Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study

Objective: Mutational analysis of BCR::ABL1 kinase domain (KD) is a crucial component of clinical decision algorithms for chronic myeloid leukemia (CML) patients with failure or warning responses to tyrosine kinase inhibitor (TKI) therapy. This study aimed to detect BCR::ABL1 KD mutations in CML pat...

Full description

Bibliographic Details
Published in:BMC Research Notes
Main Author: Seman Z.A.; Ahid F.; Kamaluddin N.R.; Sahid E.N.M.; Esa E.; Said S.S.M.; Azman N.; Mat W.K.D.W.; Abdullah J.; Ali N.A.; Khalid M.K.N.M.; Yusoff Y.M.
Format: Article
Language:English
Published: BioMed Central Ltd 2024
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85191066262&doi=10.1186%2fs13104-024-06772-1&partnerID=40&md5=16f88fbdbffb24943a32696ab1a72323

Similar Items